Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.
Queensland Bauxite Ltd (ASX:QBL) provides the Company's Quarterly Activities Report.
Nanollose Limited (ASX:NC6) is pleased to provide its Appendix 4C Cash flow Statement for the quarter ending 31 March 2018, together with the following operational update.
Nanollose Limited (ASX:NC6) advises that it has completed the mailing of the Prospectus lodged with ASIC and ASX dated 16 April 2018. The Company confirms that the Offer is now open.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.
Members of the Queensland Bauxite (ASX:QBL) management team responsible for the development of the South Johnstone Bauxite Project, headed by QBL's Chief Geoscientist Dr Robert Coenraads PhD, are currently visiting several Chinese bauxite refineries and aluminium smelters whose executives have expressed interest in partnering in the development of our South Johnstone Bauxite Project.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 31 March 2018 (Q3 FY2018) and is pleased to provide a review of progress made during the quarter.
